Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study

Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, Kiyotaka Yamazaki, Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango, Yoshiya Tanaka

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. Methods: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. Results: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. Conclusions: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. Funding: AbbVie GK and Eisai Co., Ltd. Trial Registration: ClinicalTrials.gov identifier, NCT01346488.

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - 2017 Jan 31

Fingerprint

Rheumatoid Arthritis
Safety
Blood Sedimentation
Rheumatology
Adalimumab
Biological Products
Methotrexate
Japan
Cohort Studies
Health
Therapeutics

Keywords

  • Patient safety
  • Post-marketing surveillance study
  • Rheumatoid arthritis
  • TNF inhibitor
  • Work productivity and activity impairment

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis : Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. / Takeuchi, Tsutomu; Nakajima, Ryo; Komatsu, Shuichi; Yamazaki, Kiyotaka; Nakamura, Tomohiro; Agata, Naoki; Igarashi, Ataru; Tango, Toshiro; Tanaka, Yoshiya.

In: Advances in Therapy, 31.01.2017, p. 1-17.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Nakajima, Ryo ; Komatsu, Shuichi ; Yamazaki, Kiyotaka ; Nakamura, Tomohiro ; Agata, Naoki ; Igarashi, Ataru ; Tango, Toshiro ; Tanaka, Yoshiya. / Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis : Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. In: Advances in Therapy. 2017 ; pp. 1-17.
@article{b3493dc98c374da4b18d7b3a4a7c8a7c,
title = "Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study",
abstract = "Introduction: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. Methods: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. Results: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-na{\"i}ve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23{\%}. Conclusions: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. Funding: AbbVie GK and Eisai Co., Ltd. Trial Registration: ClinicalTrials.gov identifier, NCT01346488.",
keywords = "Patient safety, Post-marketing surveillance study, Rheumatoid arthritis, TNF inhibitor, Work productivity and activity impairment",
author = "Tsutomu Takeuchi and Ryo Nakajima and Shuichi Komatsu and Kiyotaka Yamazaki and Tomohiro Nakamura and Naoki Agata and Ataru Igarashi and Toshiro Tango and Yoshiya Tanaka",
year = "2017",
month = "1",
day = "31",
doi = "10.1007/s12325-017-0477-z",
language = "English",
pages = "1--17",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis

T2 - Large-Scale, Prospective, Single-Cohort ANOUVEAU Study

AU - Takeuchi, Tsutomu

AU - Nakajima, Ryo

AU - Komatsu, Shuichi

AU - Yamazaki, Kiyotaka

AU - Nakamura, Tomohiro

AU - Agata, Naoki

AU - Igarashi, Ataru

AU - Tango, Toshiro

AU - Tanaka, Yoshiya

PY - 2017/1/31

Y1 - 2017/1/31

N2 - Introduction: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. Methods: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. Results: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. Conclusions: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. Funding: AbbVie GK and Eisai Co., Ltd. Trial Registration: ClinicalTrials.gov identifier, NCT01346488.

AB - Introduction: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. Methods: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. Results: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. Conclusions: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. Funding: AbbVie GK and Eisai Co., Ltd. Trial Registration: ClinicalTrials.gov identifier, NCT01346488.

KW - Patient safety

KW - Post-marketing surveillance study

KW - Rheumatoid arthritis

KW - TNF inhibitor

KW - Work productivity and activity impairment

UR - http://www.scopus.com/inward/record.url?scp=85011317414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011317414&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0477-z

DO - 10.1007/s12325-017-0477-z

M3 - Article

C2 - 28144917

AN - SCOPUS:85011317414

SP - 1

EP - 17

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -